AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19602554
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone + Testosterone (GH+T)
Trial: 15117375
Drug: Benzoyl peroxide/clindamycin
RxNorm normalized name: BENZOYL PEROXIDE/CLINDAMYCIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide/clindamycin topical gel (5% benzoyl peroxide and 1% clindamycin)
Trial: 15117375
Drug: Benzoyl peroxide/clindamycin
RxNorm normalized name: BENZOYL PEROXIDE/CLINDAMYCIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide/clindamycin topical gel
Trial: 12478408
Drug: Oral valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valacyclovir (2 g q.i.d.)
Trial: 8012963
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) at 3.9 mg/kg and Ciprofloxacin (Cipro) 500 mg p.o. every 12 h on days 1-5 and 10-20.
Trial: 2595345
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg daily
Trial: 28028737
Drug: 1-month sustained-release
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-month sustained-release triptorelin
Trial: 28028737
Drug: 3-month sustained-release
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-month sustained-release triptorelin
Trial: 28028737
Drug: 6-month sustained-release
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month sustained-release triptorelin
Trial: 28028737
Drug: 9-month sustained-release
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-month sustained-release triptorelin
Trial: 28028737
Drug: 12-month sustained-release
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month sustained-release triptorelin
Trial: 23370795
Drug: 0.1 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/70 kg i.v. buprenorphine in humans
Trial: 23370795
Drug: 0.04 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mg/kg i.v. buprenorphine in rats
Trial: 23370795
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg i.v. buprenorphine in rats
Trial: 8957980
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 1000 ml (Group C)
Trial: 8957980
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 500 ml (Group B)
Trial: 31172873
Drug: Chewing gum
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewing gum containing 7.5 mg of sodium metaphosphate (SMP)
Trial: 26681715
Drug: LY2409021 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2409021 20 mg
Trial: 26659938
Drug: Restylane‐L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restylane‐L
Trial: 22311679
Drug: Outpatient chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient chemotherapy with S-1 + cisplatin (S-1: 80-120 mg days 1-21; cisplatin: 60 mg/m2 day 8, every 4-5 weeks)
Trial: 22311679
Drug: Inpatient chemotherapy
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient chemotherapy with intravenous hydration (control group)
Trial: 8947984
Drug: Restrictive formulary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive formulary (dosage strengths of 25, 50, 100, 125, and 150 micrograms)
Trial: 8947984
Drug: Nonrestrictive formulary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonrestrictive formulary (dosage strengths of 25, 50, 75, 100, 112, 125, 150, 175, 200, and 300 micrograms)
Trial: 7104460
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 40 mg oral propranolol hydrochloride tablets
Trial: 7104460
Drug: Innovator's product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovator's product (reference tablet)
Trial: 30916379
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg every week (ADAew)
Trial: 27301417
Drug: Indacaterol/glycopyrronium (IND/GLY)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily (OD)
Trial: 24526247
Drug: Acetaminophen/tramadol 325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen/tramadol 325 mg/37.5 mg per capsule, maximum acetaminophen 1,950 mg and tramadol 225 mg per day; treatment duration 2 weeks.
Trial: 24526247
Drug: Placebo, titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, titrated identically to treatment.
Trial: 19460715
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy combined with trastuzumab
Trial: 15867582
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (0.05 mg/kg per day)
Trial: 12062539
Drug: High-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspirin (1000 mg bolus given 1 day before angioplasty)
Trial: 12062539
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (100 mg/day only)
Trial: 12062539
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no aspirin intervention)
Trial: 9828247
Drug: High-dose epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose epinephrine (5 mg each, up to 15 doses)
Trial: 9828247
Drug: Standard-dose epinephrine
RxNorm normalized name: epinephrine Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose epinephrine (1 mg each, up to 15 doses)
Trial: 10220206
Drug: Soluble insulin
RxNorm normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soluble insulin + NPH (20‐30 min before each meal and NPH at bedtime)
Trial: 1703916
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by definitive radiation therapy (RT) - 70 Gy to involved areas and 50 Gy to uninvolved neck at 2 Gy/fraction, five fractions per week.
Trial: 1703916
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy and radiation therapy (RT) - 60 Gy to involved areas and 50 Gy to uninvolved neck in three courses of 20 Gy each, 2 Gy/fraction, ten fractions/2 weeks alternated with four courses of chemotherapy.
Trial: 29304531
Drug: Dietary nitrate
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary nitrate supplement (SiS nitrate gel)
Trial: 23290154
Drug: Theophylline plus
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline plus SFC (200 mg theophylline plus 50/250 μg SFC)
Trial: 23290154
Drug: SFC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC plus placebo (placebo tablet plus 50/250 μg SFC)
Trial: 31605923
Drug: Budesonide/glycopyrrolate/formoterol fumarate
RxNorm normalized name: budesonide/glycopyrrolate/formoterol fumarate 160 mcg-9 mcg-4.8 mcg/actuation INHALATION HFA AEROSOL WITH ADAPTER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) 320/18/9.6 μg
Trial: 31605923
Drug: Budesonide/glycopyrrolate/formoterol fumarate
RxNorm normalized name: budesonide/glycopyrrolate/formoterol fumarate 160 mcg-9 mcg-4.8 mcg/actuation INHALATION HFA AEROSOL WITH ADAPTER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) 160/18/9.6 μg
Trial: 31605923
Drug: Glycopyrrolate/formoterol fumarate
RxNorm normalized name: glycopyrrolate/formoterol fumarate 9/4.8 MCG/INHAL Metered Dose Inhaler, 120 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate/formoterol fumarate (GFF) MDI 18/9.6 μg
Trial: 31605923
Drug: Budesonide/formoterol fumarate
RxNorm normalized name: budesonide/formoterol fumarate 80/4.5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol fumarate (BFF) MDI 320/9.6 μg
Trial: 29284320
Drug: Inhaled laninamivir
RxNorm normalized name: laninamivir
DrugBank: Laninamivir (DB12791)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled laninamivir
Trial: 23877621
Drug: Warfarin maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin maintenance dosing algorithm
Trial: 9894360
Drug: Retinyl propionate
RxNorm normalized name: Retinyl Propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinyl propionate cream
Trial: 2653717
Drug: Cefotaxime (CTX)
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotaxime (CTX) 200 mg/kg/day
Trial: 27324833
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of instructor and device feedback (IDFB)
Trial: 21824799
Drug: 0.625 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/day of conjugated equine estrogens
Trial: 30797386
Drug: Alcohol Behavioral
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol Behavioral Couple Therapy (ABCT)
Trial: 19309184
Drug: Alcohol Behavioral
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol Behavioral Individual Therapy (ABIT)
Trial: 16886978
Drug: Rufinamide 200
RxNorm normalized name: rufinamide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufinamide 200 mg/day
Trial: 16886978
Drug: Rufinamide 400
RxNorm normalized name: rufinamide 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufinamide 400 mg/day
Trial: 16886978
Drug: Rufinamide 800
RxNorm normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rufinamide 800 mg/day
Trial: 16886978
Drug: Rufinamide 1600
RxNorm normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rufinamide 1600 mg/day
Trial: 15260911
Drug: rilmenidine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilmenidine 3 mg once daily
Trial: 7895460
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and Glibenclamide (MGL)
Trial: 7895460
Drug: Monotherapy (Metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (Metformin or Glibenclamide)
Trial: 7895460
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Metformin and Glibenclamide)
Trial: 2441013
Drug: Monthly group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly group sessions with videotapes for diabetic persons with low literacy skills
Trial: 2441013
Drug: Monthly group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly group sessions without videotapes
Trial: 2441013
Drug: No monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No monthly sessions
Trial: 19077067
Drug: Conservative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative management with medium chain triglyceride-enriched diet or total parenteral nutrition in combination with adequate drainage of pleural fluid
Trial: 19077067
Drug: Somatostatin or
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin or octreotide therapy
Trial: 10528370
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human bone morphogenetic protein 2 treatment groups
Trial: 2139285
Drug: Recombinant yeast-derived
RxNorm normalized name: YEAST CELL,LIVE DERIVATIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant yeast-derived hepatitis B vaccine (YDV) 20 micrograms, administered according to a 0, 1, 6 month schedule.
Trial: 507790
Drug: Ideal body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ideal body weight for AMG dosage calculation
Trial: 21323524
Drug: pegfilgrastim 6
RxNorm normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegfilgrastim 6 mg on day +1
Trial: 21323524
Drug: filgrastim (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: filgrastim (daily starting at median day +7)
Trial: 19369086
Drug: Lisinopril (postoperatively)
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril (postoperatively)
Trial: 19369086
Drug: No angiotensin
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No angiotensin converting enzyme inhibitor (control group)
Trial: 16496034
Drug: Naltrexone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone treatment (adherent)
Trial: 8182270
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of 25 units iHAV i.m. given 1 or 2 months after primary immunization
Trial: 8182270
Drug: 0.06 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 ml/kg IG i.m. given once
Trial: 29703262
Drug: Migalastat 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migalastat 150 mg every other day
Trial: 27107523
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of hyperbaric bupivacaine 0.25% plus 1mL of sufentanil
Trial: 27107523
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of hyperbaric bupivacaine 0.25% plus 1mL of placebo
Trial: 22078217
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) group treatment
Trial: 20729016
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice (500 mL/d) with aerobic training (1h, 3 times a week for 3 months)
Trial: 9182022
Drug: FAC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC plus dexrazoxane (administered after six courses of FAC)
Trial: 8314510
Drug: Steroids (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids (1 mg/kg/day of prednisone)
Trial: 30958316
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment (BMT), n=20
Trial: 30028478
Drug: Subcostal TAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcostal TAP block in addition to intravenous analgesic regimen (group II)
Trial: 30028478
Drug: Intravenous analgesic
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous analgesic regimen alone (group I)
Trial: 27480203
Drug: Nurse-initiated protocol
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nurse-initiated protocol for acetaminophen administration for patients with pain or fever
Trial: 23227682
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Shu‐stream and Ying‐spring acupoints (group A)
Trial: 18922041
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of vitamin K1 daily
Trial: 15838417
Drug: Telephone administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone administration of the Stroke Impact Scale (SIS)
Trial: 15838417
Drug: Mail administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mail administration of the Stroke Impact Scale (SIS)
Trial: 14503058
Drug: Dandi Tablet
RxNorm normalized name: Titanium Dioxide 0.18 g in 4.5 g TOPICAL LIPSTICK [3CE CRE AMY LIP COLOR 08 LADI DADI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dandi Tablet (DDT), 4 tablets twice a day for 3 months
Trial: 14503058
Drug: Nylestriol, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nylestriol, 5 mg every month for 3 months
Trial: 10936116
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 100 microg once daily
Trial: 10903487
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 200 microg once daily
Trial: 10903487
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 500 microg once daily
Trial: 27764799
Drug: Polymeric nanoparticle
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymeric nanoparticle containing docetaxel (PNP‐DTX) at 75 mg/m2
Trial: 27764799
Drug: Polymeric nanoparticle
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymeric nanoparticle containing docetaxel (PNP‐DTX) at 60 mg/m2
Trial: 27764799
Drug: Polymeric nanoparticle
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymeric nanoparticle containing docetaxel (PNP‐DTX) at 45 mg/m2
Trial: 27764799
Drug: Docetaxel (DTX)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (DTX) at 75 mg/m2
Trial: 20422942
Drug: New donepezil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New donepezil 10 mg formulation (test formulation)
Trial: 16724375
Drug: Training program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training program for general practitioners on pain management (relationships and communication, pain evaluation, prescription, negotiation of a patient contract)
Trial: 8649620
Drug: Low-dose desferrioxamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose desferrioxamine (DFO) 5 mg/kg administered 5 hours prior to dialysis (group I: n = 14)
Trial: 8649620
Drug: Low-dose desferrioxamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose desferrioxamine (DFO) 5 mg/kg administered in the conventional way (group II: n = 27)
Trial: 8649620
Drug: Low-dose desferrioxamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose desferrioxamine (DFO) treatment
Trial: 1462278
Drug: Anti-inflammatory complex
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory complex therapy with Mydocalm
Trial: 1462278
Drug: Anti-inflammatory complex
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory complex therapy (control)
Trial: 6723838
Drug: N-acetylcysteine in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine in combination with inhaled terbutaline
Trial: 23849625
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate plus formoterol (FL/F) 250/12 μg b.i.d. via dry powder inhaler (DPI)
Trial: 23849625
Drug: Budesonide plus
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide plus formoterol (BD/F) 400/12 μg b.i.d.
Trial: 22052266
Drug: Small gel-particle
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small gel-particle hyaluronic acid (SGP-HA)
Trial: 22052266
Drug: Large gel-particle
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large gel-particle hyaluronic acid (LGP-HA)
Trial: 16495194
Drug: Thymosin alpha(1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin alpha(1) 11.6 mg subcutaneously daily for 7 days
Trial: 16495194
Drug: Saline 2
RxNorm normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 2 ml daily for 7 days (Control)
Trial: 11386491
Drug: naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naltrexone 50 mg/day